Trial Profile
A phase II trial of Tocilizumab in anti-TNF refractory patients with JIA associated uveitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Uveitis
- Focus Therapeutic Use
- Acronyms APTITUDE
- 20 Mar 2019 Status changed from active, no longer recruiting to completed.
- 02 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Dec 2015 Accrual to date is 4% according to United Kingdom Clinical Research Network.